Prosensa Reports Initial Findings from the Further Clinical Data Analyses of Drisapersen for the Treatment of Duchenne Muscular Dystrophy

Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceuticalcompany focusing on RNA-modulating therapeutics for rare diseaseswith high unmet medical need, today announced initial findings fromfurther analyses from the aggregate data from the clinicaldevelopment program of drisapersen for the treatment of DuchenneMuscular Dystrophy (DMD)."We are encouraged by these results that suggestthat treating earlier in the disease and treating longer shows adelay in the progression of the disease," said Hans Schikan,Prosensa's Chief Executive Officer. "These data encourage us toengage patient groups, clinical experts and regulators to explore apath forward for drisapersen, which includes the possibility ofre-dosing."Schikan will be presenting details of thefurther data analyses at the 32nd Annual J.P. MorganHealthcare Conference in San Francisco on Thursday, January 16,2014 at 10:00 AM Pacific Time. A live webcast of the presentationcan be accessed through the Investors & Media section of theProsensa corporate website at http://ir.prosensa.eu/events.cfm and will be archived for 90 days.With data from more than 300 patients Prosensahas the largest clinical data set in DMD. In order to advance thegeneral understanding of DMD, Prosensa has also announced that itwill make certain data from the drisapersen clinical programavailable to the scientific community. In addition it has initiateda See full press release